Advertisement
ABBV vs AMGN
Which Stock Would AI Choose? AbbVie (ABBV) vs. Amgen (AMGN) Stock Comparison
Key Takeaways
- Both ABBV and AMGN are large-cap, dividend-paying biopharmaceutical leaders, but they differ sharply in scale, growth mix, and near-term catalysts.
- ABBV delivered double-digit revenue growth, raised full-year guidance, and increased its dividend in its latest quarter, signaling durable execution through patent expirations.
- AMGN also beat estimates and raised its outlook, but carries larger loss-of-exclusivity headwinds and a more mixed analyst consensus.
- Tickeron AI Verdict: On current trend consistency, relative positioning, and catalyst visibility, the AI framework favors ABBV over AMGN.
- For deeper coverage, explore ABBV Major News, ABBV Today's Price Move, AMGN Major News, and AMGN Today's Price Move.
- Discover curated, market-ready strategies on the Trending AI Robots page.
Introduction
AbbVie and Amgen are two of the largest and most closely watched names in the U.S. biopharmaceutical sector, yet they offer investors meaningfully different profiles. AbbVie, a diversified pharma giant, has spent recent years transitioning beyond its former blockbuster Humira toward newer immunology and neuroscience franchises. Amgen, a pioneering biotechnology company, is navigating its own patent cycle while investing heavily in next-generation obesity and cardiovascular programs. This stock comparison is relevant for income-oriented investors evaluating dividend durability, as well as growth investors assessing which pipeline and relative performance profile appears better positioned in the current market environment.
ABBV Overview and Recent Performance
ABBV, AbbVie Inc., is a global, research-driven biopharmaceutical company with leadership positions across immunology, neuroscience, oncology, and aesthetics. In its most recent quarterly results, the company reported revenue of roughly $17.4 billion, up about 10% year over year, and adjusted earnings per share (EPS) of $3.82, which exceeded analyst expectations. The company also raised its full-year outlook and increased its quarterly dividend by 5.2%, underscoring management's confidence in cash generation.
Recent market activity has been shaped by the continued strength of immunology treatments Skyrizi and Rinvoq, which together more than offset the ongoing decline of Humira as biosimilar competition intensifies. Neuroscience products such as Vraylar and newer migraine therapies have also contributed momentum, while aesthetics remains the portfolio's softer area. Regulatory approvals and a completed acquisition have reinforced a broad, durable growth narrative that has supported positive sentiment in recent weeks.
AMGN Overview and Recent Performance
AMGN, Amgen Inc., is a biotechnology pioneer headquartered in Thousand Oaks, California, with a diversified portfolio spanning general medicine, oncology, rare disease, inflammation, and biosimilars. In its most recent reported quarter, Amgen posted revenue of roughly $10 billion, up about 9% year over year, with adjusted EPS that comfortably beat Wall Street consensus. Management subsequently raised its full-year revenue and earnings guidance.
Amgen's performance has been driven by a set of fast-growing products, including Repatha, Evenity, and rare-disease therapies, which are offsetting erosion in legacy drugs such as Prolia and Enbrel as biosimilars and government pricing policies take effect. The company has also refocused its obesity ambitions around MariTide following the discontinuation of an earlier candidate, with pivotal data expected in the years ahead. While growth remains solid, analyst consensus is more cautious, and the stock carries a relatively rich valuation against mixed forward expectations.
Trending AI Robots
Tickeron maintains a large library of AI trading bots that collectively trade thousands of different tickers, each built with its own trading style, strategy, timeframe, performance record, and universe of stocks. Because market conditions are constantly shifting, only a small subset of these bots is well suited to the current environment. The Trending AI Robots page curates that select group, highlighting the strategies whose recent statistics and setups align best with prevailing market dynamics. For traders comparing names like ABBV and AMGN, this resource offers a practical way to see how quantitative systems are positioning in real time. Explore the Trending AI Robots page to review the currently featured bots and their performance metrics.
Head-to-Head Comparison
The two companies differ most in business-model focus and exposure. ABBV skews toward immunology and neuroscience, with a diversified but more concentrated reliance on a few blockbuster franchises. AMGN spans a broader set of therapeutic areas and adds a biosimilars business and a high-profile obesity pipeline. In terms of scale, AbbVie's market capitalization is roughly double Amgen's, and its dividend-growth trajectory has been more consistent recently, while both offer comparable dividend yields.
On momentum, AbbVie's latest quarter showed accelerating revenue growth with clear guidance raises, whereas Amgen's growth is steadier but faces larger patent-expiration erosion and a more mixed analyst stance. Risk profiles also differ: AbbVie must sustain growth as Humira fades and Skyrizi's growth rate moderates, while Amgen contends with biosimilar pressure on Prolia and Enbrel and the inherent uncertainty of late-stage obesity trials. Sentiment currently appears more constructive around AbbVie's execution, while Amgen trades at a premium relative to its consensus price target.
Tickeron AI Verdict
Based on observable factors such as trend consistency, guidance momentum, dividend durability, and relative positioning, Tickeron's AI framework currently leans toward ABBV over AMGN. AbbVie's combination of double-digit top-line growth, successive guidance increases, and a rising dividend points to steadier near-term momentum and clearer catalysts. Amgen remains a strong, diversified operator, but its larger loss-of-exclusivity overhang and more cautious analyst consensus introduce greater variability. This assessment is probabilistic rather than definitive and reflects current market data rather than a long-term fundamental judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and AMGN is a Hold.
ABBV's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ABBV turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 52 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 213 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-87.802) is very low in comparison to the industry average of (-1.376). ABBV has a moderately high P/E Ratio (83.302) as compared to the industry average of (21.842). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.039) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 45 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 148 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.555) is normal, around the industry mean (-1.376). P/E Ratio (28.731) is within average values for comparable stocks, (21.842). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.039) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
ABBV | AMGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 2 | 4 | |
SMR RATING 1..100 | 1 | 15 | |
PRICE GROWTH RATING 1..100 | 9 | 6 | |
P/E GROWTH RATING 1..100 | 89 | 22 | |
SEASONALITY SCORE 1..100 | 44 | 23 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for AMGN (79) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than AMGN’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as AMGN (4) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as AMGN (15) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's Price Growth Rating (6) in the Biotechnology industry is in the same range as ABBV (9) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to ABBV’s over the last 12 months.
AMGN's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for ABBV (89) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than ABBV’s over the last 12 months.
| ABBV | AMGN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 33% | 3 days ago 54% |
| Stochastic ODDS (%) | 3 days ago 48% | 3 days ago 48% |
| Momentum ODDS (%) | 3 days ago 68% | 3 days ago 62% |
| MACD ODDS (%) | 3 days ago 74% | N/A |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 63% |
| TrendMonth ODDS (%) | 3 days ago 64% | 3 days ago 60% |
| Advances ODDS (%) | 3 days ago 61% | 3 days ago 62% |
| Declines ODDS (%) | 5 days ago 46% | 14 days ago 47% |
| BollingerBands ODDS (%) | 3 days ago 43% | 3 days ago 53% |
| Aroon ODDS (%) | 3 days ago 61% | 3 days ago 54% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while AMGN’s FA Score has 4 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- AMGN’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while AMGN’s TA Score has 5 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 4 bearish.
- AMGN’s TA Score: 5 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +3.24% price change this week, while AMGN (@Pharmaceuticals: Major) price change was +6.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.16%. For the same industry, the average monthly price growth was -2.39%, and the average quarterly price growth was +4.91%.
Reported Earning Dates
ABBV is expected to report earnings on Feb 03, 2027.
AMGN is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.16% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with JNJ. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then JNJ could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +1.41% | ||
| JNJ - ABBV | 51% Loosely correlated | -0.73% | ||
| NVS - ABBV | 49% Loosely correlated | -0.19% | ||
| AMGN - ABBV | 48% Loosely correlated | +1.15% | ||
| BMY - ABBV | 47% Loosely correlated | +1.78% | ||
| MRK - ABBV | 42% Loosely correlated | +2.18% | ||
More | ||||